UNLABELLED: This was a single-agent phase II clinical trial of the antifol piritrexim in patients with advanced transitional cell carcinoma of the bladder. METHODS: Patients with previously-treated, advanced urothelial carcinoma were treated with oral piritrexim at a dose of 25 mg three times daily for 5 consecutive days each week for 3 consecutive weeks followed by a 1-week rest period. Courses were repeated every 28 days. RESULTS: Thirty-five patients were enrolled in the study, with 28 patients evaluable for survival and toxicity and 27 evaluable for response. TOXICITY: Myelosuppression was the major dose-limiting toxicity, with WHO grade 3/4 thrombocytopenia in 4 patients, granulocytopenia in 1 patient, and anemia in 3 patients. Grade 3 nonhematologic toxicity consisted of neuropathy in 5 patients, hepatotoxicity in 2, nausea in 2, and 1 each with pulmonary toxicity and rash. EFFICACY: Of the 27 patients evaluable for response, 2 (7%) achieved an objective response, lasting 112 and 142 days, respectively. CONCLUSION: Piritrexim has minimal activity in patients with previously treated transitional cell carcinoma of the bladder, regardless of prior exposure to methotrexate, and further evaluation of this compound in this clinical setting is not warranted.
UNLABELLED: This was a single-agent phase II clinical trial of the antifol piritrexim in patients with advanced transitional cell carcinoma of the bladder. METHODS:Patients with previously-treated, advanced urothelial carcinoma were treated with oral piritrexim at a dose of 25 mg three times daily for 5 consecutive days each week for 3 consecutive weeks followed by a 1-week rest period. Courses were repeated every 28 days. RESULTS: Thirty-five patients were enrolled in the study, with 28 patients evaluable for survival and toxicity and 27 evaluable for response. TOXICITY: Myelosuppression was the major dose-limiting toxicity, with WHO grade 3/4 thrombocytopenia in 4 patients, granulocytopenia in 1 patient, and anemia in 3 patients. Grade 3 nonhematologic toxicity consisted of neuropathy in 5 patients, hepatotoxicity in 2, nausea in 2, and 1 each with pulmonary toxicity and rash. EFFICACY: Of the 27 patients evaluable for response, 2 (7%) achieved an objective response, lasting 112 and 142 days, respectively. CONCLUSION:Piritrexim has minimal activity in patients with previously treated transitional cell carcinoma of the bladder, regardless of prior exposure to methotrexate, and further evaluation of this compound in this clinical setting is not warranted.
Authors: G R Weiss; G A Sarosy; T D Shenkenberg; T Williams; N J Clendeninn; D D Von Hoff; J L Woolley; S H Liao; M R Blum Journal: Eur J Cancer Clin Oncol Date: 1989-12
Authors: D J Vaughn; S B Malkowicz; B Zoltick; R Mick; P Ramchandani; C Holroyde; B Armstead; K Fox; A Wein Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: L G Feun; N Savaraj; P Benedetto; J Hanlon; K S Sridhar; M Collier; S Richman; S H Liao; N J Clendeninn Journal: J Natl Cancer Inst Date: 1991-01-02 Impact factor: 13.506
Authors: B J Roth; R Dreicer; L H Einhorn; D Neuberg; D H Johnson; J L Smith; G R Hudes; S M Schultz; P J Loehrer Journal: J Clin Oncol Date: 1994-11 Impact factor: 44.544
Authors: Gonzalo Gomez-Abuin; Eric Winquist; Walter M Stadler; Greg Pond; Pamela Degendorfer; John Wright; Malcolm J Moore Journal: Invest New Drugs Date: 2006-09-16 Impact factor: 3.850
Authors: Karin Holmsten; Line Dohn; Niels Viggo Jensen; Carl-Henrik Shah; Fredrik Jäderling; Helle Pappot; Anders Ullén Journal: Oncol Lett Date: 2016-06-23 Impact factor: 2.967